Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3185-8. doi: 10.1158/1055-9965.EPI-10-0942. Epub 2010 Oct 8.

Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Author information

1
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, Seattle, WA 98109-1024, USA. tbrasky@fhcrc.org

Abstract

INTRODUCTION:

Chronic inflammation may be important in prostate carcinogenesis. Several epidemiologic studies have reported inverse associations between nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk, although many studies are limited by assessment of short-term use only.

METHODS:

Participants were male members of the VITamins And Lifestyle cohort, comprised 34,132 men, aged 50-76 years, living in western Washington State. Cox proportional hazards models were used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) of 10-year average use of individual NSAIDs with total prostate cancer (n = 1,550) and prostate cancer by grade.

RESULTS:

Low-dose aspirin, regular-strength aspirin, ibuprofen, and any nonaspirin NSAID (ibuprofen, naproxen, and COX-2 inhibitors) were not associated with prostate cancer risk. There was a suggestion that regular-strength aspirin was inversely associated with risk of high-grade cancer (HR 0.73, 95% CI: 0.53-1.02).

CONCLUSION:

NSAID use was not associated with prostate cancer risk in the VITAL cohort.

IMPACT:

Our findings do not support the use of NSAIDs for chemoprevention of prostate cancer.

PMID:
20935064
PMCID:
PMC3005534
DOI:
10.1158/1055-9965.EPI-10-0942
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center